“The US FDA had conducted an inspection at the Company's manufacturing facility located at Amaliya, Daman, India from 19th March, 2018 to 27th March, 2018. Post the inspection, the Company has received a Form 483 with thirteen observations,” Alkem Labs said in a regulatory filing.
The company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA observations and the same is proposed to be filed within the timeline stipulated by the US FDA, it added.
Alkem Labs also said that US FDA had conducted an inspection at the Company's manufacturing facility located at St. Louis, USA from 12th March, 2018 to 16th March, 2018.
In response to the one Form 483 observation issued by the US FDA, the Company has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines, it added.
At 01:35 pm; the stock was trading 9% lower at Rs 1,897 as compared to 0.49% decline in the S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 331,734 shares changed hands on the BSE and NSE so far.
Subscribe To Insights
Key stories on business-standard.com are available to premium subscribers only.
Already a BS Premium subscriber? LOGIN NOW₹249
₹1499₹1799
Opt for auto renewal and save Rs 300
₹1799
What you get on Business Standard Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.